Apr 30, 2020
Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech's Ocrevus on the Rise, Biogen's Tecfidera Declines, and Teva's Copaxone Remains Strong, According to Spherix Global Insights
Jan 06, 2020
Teva Pharmaceuticals Agrees To Pay $54 Million To Settle Shepherd, Finkelman, Miller & Shah, LLP False Claims Act Qui Tam Case
Mar 27, 2019
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Oct 12, 2018
Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court
May 29, 2018
Teva Launches Life Effects Website at IAPO 8th Global Patients Congress
Apr 25, 2018
Recent Chart Audit of Multiple Sclerosis Patients Recently Switched to a New Disease-Modifying Therapy Shines Spotlight on Gains by Genentech's Ocrevus in the Secondary Progressive and Primary Progressive Patient Segments
Apr 21, 2018
Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting
Apr 10, 2018
Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Feb 13, 2018
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Dec 11, 2017
Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL
Nov 07, 2017
Decision Resources Group Projects G7 Sales Of The Multiple Sclerosis Market To Exceed $25 Billion In The Next Decade
Oct 26, 2017
Mylan Wins UK Court Ruling Related to Copaxone® 40 mg/mL Patent
Oct 05, 2017
Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mL
Oct 04, 2017
Mylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and Generic for Copaxone® 20 mg/mL Once-Daily
Oct 04, 2017
FDA Approval of Mylan's Glatiramer Acetate Will Turn the Payer Pressure On for Teva's Copaxone and Sandoz's Glatopa
Oct 03, 2017
Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity